Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942710 | 0.91 | GPR119 (0.47) | GPR119HSD11B1TEAD1TEAD3PDK2 | |
| SCHEMBL14097819 | 0.90 | GPR119 (0.41) | GPR119TEAD1TEAD3PDK2MCHR1 | |
| SCHEMBL3632575 | 0.89 | GPR119 (0.47) | GPR119HSD11B1TEAD1TEAD3MCHR1 | |
| SCHEMBL943004 | 0.86 | HSD11B1 (0.44) | HSD11B1 | |
| SCHEMBL3722073 | 0.84 | ITGB3 (0.40) | GPR119TEAD1TEAD3 | |
| SCHEMBL945292 | 0.84 | GPR119 (0.47) | GPR119HSD11B1TEAD1TEAD3MCHR1 | |
| SCHEMBL945293 | 0.83 | GPR119 (0.43) | GPR119HSD11B1TEAD1TEAD3MCHR1 | |
| SCHEMBL944330 | 0.82 | GPR119 (0.45) | GPR119HSD11B1MCHR1 | |
| SCHEMBL14097741 | 0.81 | GPR119 (0.43) | GPR119TEAD1TEAD3PDK2MCHR1 | |
| SCHEMBL14097613 | 0.81 | GPR119 (0.36) | GPR119HSD11B1TEAD1TEAD3CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | claimed |
| EP-2146952-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008101885-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | claimed |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| EP-2146952-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2125704-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101886-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101885-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | GPR119 453/4885HSD11B1 1/4885TEAD1 3553/4885 |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | GPR119 453/4885HSD11B1 1/4885TEAD1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.